146 related articles for article (PubMed ID: 31402602)
1. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.
Caceres Guido P; Perez M; Halac A; Ferrari M; Ibarra M; Licciardone N; Castaños C; Gravina LP; Jimenez C; Garcia Bournissen F; Schaiquevich P
Pediatr Pulmonol; 2019 Nov; 54(11):1801-1810. PubMed ID: 31402602
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.
Illamola SM; Huynh HQ; Liu X; Bhakta ZN; Sherwin CM; Liou TG; Carveth H; Young DC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295
[TBL] [Abstract][Full Text] [Related]
5. Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model.
Thirion DJG; Pasche V; Matouk E; Marsot A
Pediatr Pulmonol; 2020 May; 55(5):1154-1160. PubMed ID: 32119197
[TBL] [Abstract][Full Text] [Related]
6. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.
Nolt VD; Pijut KD; Autry EB; Williams WC; Burgess DS; Burgess DR; Arora V; Kuhn RJ
Pediatr Pulmonol; 2019 Jan; 54(1):33-39. PubMed ID: 30507069
[TBL] [Abstract][Full Text] [Related]
7. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
[TBL] [Abstract][Full Text] [Related]
8. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.
Vic P; Ategbo S; Turck D; Husson MO; Tassin E; Loeuille GA; Deschildre A; Druon D; Elian JC; Arrouet-Lagandre C; Farriaux JP
Eur J Pediatr; 1996 Nov; 155(11):948-53. PubMed ID: 8911895
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
Halacová M; Průsa R; Kotaska K; Vávrová V
Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
[TBL] [Abstract][Full Text] [Related]
11. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
[TBL] [Abstract][Full Text] [Related]
12. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of once-daily amikacin in healthy foals and therapeutic drug monitoring in hospitalized equine neonates.
Bucki EP; Giguère S; Macpherson M; Davis R
J Vet Intern Med; 2004; 18(5):728-33. PubMed ID: 15515591
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
Hennig S; Standing JF; Staatz CE; Thomson AH
Clin Pharmacokinet; 2013 Apr; 52(4):289-301. PubMed ID: 23420517
[TBL] [Abstract][Full Text] [Related]
16. Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis.
Rohani R; Hoff B; Jain M; Philbrick A; Salama S; Cullina JF; Rhodes NJ
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):199-209. PubMed ID: 34882292
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.
Canis F; Husson MO; Turck D; Vic P; Launay V; Ategbo S; Vincent A; Courcol RJ
J Antimicrob Chemother; 1997 Mar; 39(3):431-3. PubMed ID: 9096197
[TBL] [Abstract][Full Text] [Related]
18. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
19. A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis.
Woillard JB; Bouchet S; Fayon M; Marquet P; Monchaud C; Bui S
Ther Drug Monit; 2021 Aug; 43(4):499-504. PubMed ID: 33346630
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
